TOP > 外国特許検索 > SUGAR CHAIN MARKER AS MEASURE OF DISEASE CONDITIONS OF HEPATIC DISEASES

SUGAR CHAIN MARKER AS MEASURE OF DISEASE CONDITIONS OF HEPATIC DISEASES

外国特許コード F120006184
整理番号 S2009-0883
掲載日 2012年2月6日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2010JP061791
国際公開番号 WO 2011007764
国際出願日 平成22年7月12日(2010.7.12)
国際公開日 平成23年1月20日(2011.1.20)
優先権データ
  • 特願2009-165795 (2009.7.14) JP
発明の名称 (英語) SUGAR CHAIN MARKER AS MEASURE OF DISEASE CONDITIONS OF HEPATIC DISEASES
発明の概要(英語) Disclosed is a sugar chain marker which can detect hepatic diseases. More specifically disclosed is a sugar chain marker which can be used as a measure of the disease conditions of hepatic diseases. Further specifically disclosed is a sugar chain marker which can distinguish disease conditions depending on the stages of progression of hepatocellular carcinoma. A glycopeptide and a group of glycopeptides of which the sugar chain structure is changed specifically in hepatic diseases including hepatocellular carcinoma are identified among from serum glycoproteins. The glycopeptide and the group of glycopeptides can be used as a novel (glycopeptides and glycoprotein) sugar chain marker specific to the disease conditions of hepatic diseases.
従来技術、競合技術の概要(英語) BACKGROUND ART
Is liver cancer, primary liver cancer and occurs in the liver, can be largely divided into a metastatic liver cancer, primary liver cancer is hepatocellular carcinoma in 90% is called.
Hepatocellular cancer patients, as the underlying disease, hepatitis C virus, hepatitis B virus infection or in many cases, from acute viral hepatitis, chronic viral hepatitis, liver cirrhosis and then proceeds to the, after suffering from viral hepatitis, after a prolonged period of time, often to cancer for the first time. In cirrhosis, inflammation by repeating reproduction, when normal hepatocytes is reduced, to the organ is composed of fibrous tissue changes. For example, hepatitis C patients, only 300 million Climate, Chinese Africa is, are said to be 1000 or greater. In addition, type B, hepatitis C in case of a patient, rate from chronic hepatitis in rats, 0.8% per year (F1) in the mild chronic hepatitis, chronic hepatitis (F2) moderate but per year in 0.9%, (F3) becomes severe chronic hepatitis and 3.5% per year, further increasing the likelihood of cancer from liver cirrhosis (F4), also increases to 7% per year (Fig. 2, 3). Also liver disease can be, along with the progression of the pathological condition, first begins to disappear function in chronic hepatitis, liver cirrhosis appears in the pathological structure, such as liver fibrosis proceeds, histology changes (Fig. 1).
In the treatment of cancer, early detection of cancer is important, in the case of hepatocellular carcinoma at an early stage discovery of cancer treatment, a great effect on the postoperative prognosis. 5 - Year survival rate is hepatectomy treatment, at 80% if the stage I, stage IV is only 38%.
Liver cancer markers include, up to now, α - fetoprotein (AFP) and protein induced by Vitamin K absence or antagonist-II(PIVKA-II) is known (patent document 1, 2) is, its specificity, sensitivity is not fully. For this reason, currently, screening for the early detection of liver cancer, liver cancer marker, ultrasound, computed tomography (CT), magnetic resonance imaging (MRI) an image such as the inspection is taking place.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
  • NAGOYA CITY UNIVERSITY
  • NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE
  • 発明者(英語)
  • NARIMATSU Hisashi
  • HIRABAYASHI Jun
  • IKEHARA Yuzuru
  • ANGATA Takashi
  • KAJI Hiroyuki
  • KUNO Atsushi
  • OOKURA Takashi
  • SHIKANAI Toshihide
  • SOGABE Maki
  • TOGAYACHI Akira
  • OCHOU Makoto
  • TANAKA Yasuhito
  • MIZOKAMI Masashi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close